Alaunos Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Alaunos Therapeutics, Inc. (TCRT) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $0.00 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-03-31
- Alaunos Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $0.00.
- Alaunos Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2021-03-31 was $2.89, a 54.55% increase year-over-year.
- Alaunos Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2020-03-31 was $1.87.
- Alaunos Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2018-03-31 was $0.00, a 100.00% decline year-over-year.
- Alaunos Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $0.00.
- Alaunos Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $0.00.
- Alaunos Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Alaunos Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $12.00, a 319.58% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-31 | ||||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-14 | ||||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-14 | ||||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-15 | ||||
| 2024-12-31 | $0.00 10-K · filed 2025-03-31 | ||||
| 2023-12-31 | $0.00 10-K · filed 2025-03-31 | ||||
| 2022-12-31 | $12.00 10-K · filed 2024-04-01 | $0.80 10-K · filed 2023-03-07 | |||
| 2022-09-30 | $0.80 10-Q · filed 2022-11-14 | ||||
| 2021-12-31 | $2.86 10-K · filed 2023-03-07 | ||||
| 2021-09-30 | $2.86 10-Q · filed 2021-11-08 | ||||
| 2021-06-30 | $2.86 10-Q · filed 2021-08-13 | ||||
| 2021-03-31 | $2.89 10-Q · filed 2021-05-06 | ||||
| 2020-12-31 | $2.01 10-K · filed 2022-03-30 | ||||
| 2020-09-30 | $1.87 10-Q · filed 2020-11-05 | ||||
| 2020-06-30 | $1.87 10-Q · filed 2020-08-06 | ||||
| 2020-03-31 | $1.87 10-Q · filed 2020-05-07 | ||||
| 2019-12-31 | $3.30 10-K · filed 2021-03-01 | ||||
| 2019-09-30 | $3.48 10-Q · filed 2019-11-07 | ||||
| 2019-06-30 | $2.95 10-Q · filed 2019-08-08 | ||||
| 2018-12-31 | $2.35 10-K · filed 2021-03-01 | $2.30 10-K · filed 2019-03-05 | |||
| 2018-09-30 | $2.30 10-Q · filed 2018-11-09 | ||||
| 2018-06-30 | $2.30 10-Q · filed 2018-08-08 | ||||
| 2018-03-31 | $0.00 10-Q · filed 2018-05-10 | ||||
| 2017-12-31 | $3.67 10-K · filed 2020-03-02 | ||||
| 2017-09-30 | $4.85 10-Q · filed 2017-11-06 | ||||
| 2017-06-30 | $4.85 10-Q · filed 2017-07-31 | ||||
| 2017-03-31 | $4.89 10-Q · filed 2017-05-01 | ||||
| 2016-12-31 | $4.57 10-K · filed 2019-03-05 | ||||
| 2016-09-30 | $4.81 10-Q · filed 2016-11-09 | ||||
| 2016-06-30 | $4.81 10-Q · filed 2016-08-09 | ||||
| 2016-03-31 | $4.72 10-Q · filed 2016-05-10 | ||||
| 2015-12-31 | $3.95 10-K · filed 2018-03-01 | ||||
| 2015-09-30 | $3.96 10-Q · filed 2015-11-02 | ||||
| 2015-06-30 | $3.97 10-Q · filed 2015-08-10 | ||||
| 2015-03-31 | $4.29 10-Q · filed 2015-05-07 | ||||
| 2014-12-31 | $2.26 10-K · filed 2017-02-16 | ||||
| 2014-09-30 | $2.26 10-Q · filed 2014-10-30 | ||||
| 2014-06-30 | $2.26 10-Q · filed 2014-08-07 | ||||
| 2014-03-31 | $2.02 10-Q · filed 2014-05-08 | ||||
| 2013-12-31 | $1.68 10-K · filed 2016-02-24 | ||||
| 2013-09-30 | $1.68 10-Q · filed 2013-10-22 | ||||
| 2013-06-30 | $1.87 10-Q · filed 2013-08-08 | ||||
| 2013-03-31 | $1.88 10-Q · filed 2013-05-07 | ||||
| 2012-12-31 | $3.61 10-K · filed 2015-02-26 | ||||
| 2012-09-30 | $3.61 10-Q · filed 2012-11-08 | ||||
| 2012-06-30 | $3.61 10-Q/A · filed 2012-08-28 | ||||
| 2011-12-31 | $2.04 10-K · filed 2014-03-03 | ||||
| 2010-12-31 | $1.19 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |